Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?

CM Hull, M Peakman, TIM Tree - Diabetologia, 2017 - Springer
Type 1 diabetes is an autoimmune disease characterised by the destruction of insulin
producing beta cells in the pancreas. Whilst it remains unclear what the original triggering …

[PDF][PDF] Diabetes epidemiology as a tool to trigger diabetes research and care

PZ Zimmet - Diabetologia, 1999 - academia.edu
Abbreviations: NDDG, National Diabetes Data Group; WHO, World Health Organization;
CVD, cardiovascular disease; ADA, American Diabetes Association; IFG, impaired fasting …

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

DK Wherrett, B Bundy, DJ Becker, LA DiMeglio… - The Lancet, 2011 - thelancet.com
Background Glutamic acid decarboxylase (GAD) is a major target of the autoimmune
response that occurs in type 1 diabetes mellitus. In animal models of autoimmunity …

GAD treatment and insulin secretion in recent-onset type 1 diabetes

J Ludvigsson, M Faresjö, M Hjorth… - … England Journal of …, 2008 - Mass Medical Soc
Background The 65-kD isoform of glutamic acid decarboxylase (GAD) is a major
autoantigen in patients with type 1 diabetes mellitus. This trial assessed the ability of alum …

Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococcus lactis Reverses Diabetes in Recent-Onset NOD Mice

S Robert, C Gysemans, T Takiishi, H Korf… - Diabetes, 2014 - Am Diabetes Assoc
Growing insight into the pathogenesis of type 1 diabetes (T1D) and numerous studies in
preclinical models highlight the potential of antigen-specific approaches to restore tolerance …

B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in FcγR effector functions

Y Xiu, CP Wong, JD Bouaziz, Y Hamaguchi… - The Journal of …, 2008 - journals.aai.org
NOD mice deficient for B lymphocytes from birth fail to develop autoimmune or type 1
diabetes. To assess whether B cell depletion influences type 1 diabetes in mice with an …

Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes

CD Agardh, CM Cilio, ÅL Lethagen, K Lynch… - Journal of Diabetes and …, 2005 - Elsevier
The purpose of this Phase II study was to evaluate if alum-formulated human recombinant
GAD65 is safe and does not compromise beta cell function. The study was conducted as a …

Immune modulation in humans: implications for type 1 diabetes mellitus

BO Roep, TIM Tree - Nature Reviews Endocrinology, 2014 - nature.com
Type 1 diabetes mellitus (T1DM) is the result of autoimmune destruction of pancreatic β cells
in genetically predisposed individuals with impaired immune regulation. The insufficiency in …

Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection

M Iwashiro, RJ Messer, KE Peterson… - Proceedings of the …, 2001 - National Acad Sciences
Normal levels of CD4+ regulatory T cells are critical for the maintenance of immunological
homeostasis and the prevention of autoimmune diseases. However, we now show that the …

Immunotherapy of type 1 diabetes: where are we and where should we be going?

X Luo, KC Herold, SD Miller - Immunity, 2010 - cell.com
Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of
insulin-producing pancreatic β cells. Many broad-based immunosuppressive and antigen …